Stocks to Watch Today: Jubilant Ingrevia, Alkem Laboratories, Adani Enterprises and Others (November 9, 2026)

Indian equity markets are likely to see stock-specific movements as investors assess corporate announcements, quarterly financial performance and fresh business developments across sectors. 

Companies securing major contracts, expanding through acquisitions and reporting quarterly earnings are expected to remain on investors' radar during the trading session. 

Jubilant Ingrevia Ltd 

Jubilant Ingrevia's subsidiary, Jubilant Advanced Electronics, has entered into an agreement to acquire a 40% strategic equity stake in Zettaone Technologies India, with an option to increase its holding to 51% within the next year. 

The transaction marks the company's entry into the electronics design and manufacturing services sector, opening opportunities across semiconductor, aerospace, defence, automotive and other electronics segments. 

Alkem Laboratories Ltd 

Alkem Laboratories has incorporated a joint venture subsidiary, Alkem Pharma Company, in Saudi Arabia. The development is aimed at expanding the pharmaceutical company's operations and strengthening its business presence in the Saudi Arabian market. 

Adani Enterprises Ltd 

AdaniConneX, a joint venture involving Adani Enterprises, Vizag Mega Data Center Park Limited and Adani Infra (India), has completed the acquisition of a 100% stake in Vizag Mega Data Center Park Limited. 

Following the transaction, Vizag Mega Data Center Park Limited has become a joint venture of the company, marking a significant development in its data centre business. 

Bharat Heavy Electricals Ltd (BHEL) 

BHEL has secured an order worth ₹600 crore to ₹900 crore from Power Grid Corporation of India for installing synchronous condensers at the Barmer-II HVDC terminal station in Rajasthan. 

Under the contract, BHEL will handle the design, engineering, manufacturing, supply, installation, testing and commissioning of two synchronous condenser units at the facility. 

Tata Steel Ltd 

Tata Steel reported a 16.2% year-on-year increase in consolidated net profit to ₹3,700 crore for the September quarter of FY2027, exceeding CNBC-TV18's estimate of ₹3,120 crore. 

Operating income increased 11.5% to ₹65,436 crore from ₹58,689 crore in the corresponding quarter last year. EBITDA rose 18.4%, while the EBITDA margin stood at 16.1%, compared with 15.2% in the previous quarter. 

Siemens Ltd 

Siemens reported a 3.9% year-on-year increase in net profit to ₹504 crore for the July-September 2026 quarter, compared with ₹485 crore in the corresponding period last year. 

Operating income grew 17% to ₹5,734 crore from ₹4,900 crore. EBITDA increased 2.8% to ₹626 crore, although the EBITDA margin declined to 10.9% from 12.4% a year earlier. 

Cohance Lifesciences Ltd 

Cohance Lifesciences reported a 79.5% year-on-year decline in net profit to ₹15.2 crore in the second quarter of FY2027, compared with ₹74.1 crore in the corresponding period last year. 

Revenue declined 14.2% to ₹477 crore from ₹556 crore. However, the company reported a 12.9% increase in operating income compared with the previous quarter, reaching ₹4,767 crore. 

Voltas Ltd 

Voltas reported a 53.4% year-on-year increase in net profit to ₹52.6 crore in the second quarter of FY2027, compared with ₹34.3 crore in the corresponding quarter last year. 

Operating income increased 15.3% to ₹2,707 crore from ₹2,347 crore. The reported revenue also exceeded CNBC-TV18's estimate of ₹2,556 crore. 

Marico Ltd 

Marico has signed a definitive agreement with the founders of Bonorizon Consumer Ventures Private Limited to acquire a 51% stake in the company for a consideration of up to ₹35 crore. 

The acquisition will be completed through a primary subscription to Bonorizon's equity share capital and voting rights, subject to the agreed terms and conditions. 

Finolex Cables Ltd 

Finolex Cables reported a 67.5% year-on-year increase in profit to ₹273 crore in the second quarter of FY2027, compared with ₹163 crore in the corresponding quarter last year. 

Operating income surged 65% to ₹2,269 crore from ₹1,376 crore. EBITDA more than doubled to ₹311 crore, registering 113% growth, supported by higher sales volumes in its electrical and communication cable businesses. 

Read More: Marico Share Price in Focus; To Acquire 51% Stake in Bonorizon for ₹35 Crore! 

Insecticides (India) Ltd 

Insecticides (India) reported a 5.1% year-on-year decline in consolidated net profit to ₹56 crore in the second quarter of FY2027, compared with ₹59 crore in the corresponding period last year. 

Operating income increased 7.5% to ₹686 crore from ₹638 crore, while EBITDA rose 4.5% to ₹93 crore. The company attributed the pressure on profitability to higher interest costs, while working capital days increased to 158 in the first half of FY2027 from 151 a year earlier. 

Mahindra & Mahindra Ltd 

Mahindra & Mahindra has approved an investment of up to ₹1,450 crore in the proposed rights issue of its listed subsidiary, SML Mahindra. 

The investment includes approximately ₹855 crore towards subscribing to its full rights entitlement and an additional amount of up to ₹595 crore for further equity shares or any unsubscribed portion of the issue. 

Aarti Drugs Ltd 

Aarti Drugs' subsidiary, Pinnacle Life Sciences Private Limited, has received three inspectional observations in Form 483 from the US Food and Drug Administration following an inspection of its formulations manufacturing facility in Baddi, Himachal Pradesh. 

The regulatory inspection was conducted between November 2 and November 6, 2026. Investors will monitor further developments regarding the observations and the company's response. 

Coromandel International Ltd 

Coromandel International reported a 33.7% year-on-year decline in net profit to ₹534.2 crore in the second quarter of FY2027, compared with ₹805.3 crore in the corresponding quarter last year. 

Operating income increased 6.7% to ₹10,294 crore from ₹9,651 crore, indicating revenue growth despite a decline in quarterly profitability. 

Zydus Lifesciences Ltd 

Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences, announced results from the Phase 2b clinical trial of its experimental drug saroglitazar. 

The trial results indicated that the drug performed better than a placebo in adults with metabolic dysfunction-associated steatohepatitis (MASH), demonstrating improvement in steatohepatitis without worsening liver fibrosis. 

Vedant Poly Fabs Ltd 

Vedant Poly Fabs is scheduled to make its SME market debut on November 9, 2026. Investors will track its listing performance and market response during the trading session. 

Conclusion 

Major order wins, strategic acquisitions, regulatory developments and quarterly earnings are likely to influence stock-specific movements during today's trading session. Investors will also track upcoming financial results, dividend-related activities and SME listing developments. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.